Propanc Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2020; filed May 15, 2020. Although the request identifies “2019 Q3,” the filing covers fiscal 2020 Q3. Amounts are in U.S. dollars unless noted.
Business context
Propanc is a development-stage biotechnology company focused on cancer treatments. Its lead candidate, PRP, is a preclinical pro-enzyme formulation; the company reported no products on the market, no clinical trials underway, and no revenue. Its operations are funded primarily through convertible debt and equity financing.
Key financial metrics
| Metric | Three months ended March 31, 2020 | Nine months ended March 31, 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $607,168 | $2,900,186 |
| Operating loss | $607,168 | $2,900,186 |
| Net loss | $2,585,662 | $5,944,711 |
| Net loss per share | $0.35 | $1.79 |
- Cash flow: Nine-month operating cash use was $1,349,931, versus $1,793,805 in the comparable 2019 period. Financing provided $1,465,250; cash ended at just $26,957.
- Liquidity and debt: At March 31, current assets were $31,500 and current liabilities were $4,890,800, producing a reported working capital deficit of $4,859,300. Net convertible notes and accrued interest were $2,711,173; embedded conversion-option liabilities were $318,368. Total liabilities were $4,910,845, against total assets of $63,938.
- Equity: Stockholders’ deficit was $4,846,908 and accumulated deficit was $56,985,758. The balance sheet reported 18,481,410 common shares outstanding; the filing reported 47,086,442 issued and outstanding as of May 11, 2020.
- Margins: Not meaningful because the company had no revenue.
Changes versus the prior comparable period
- Nine-month net loss widened to $5,944,711 from $4,156,830. Operating expenses rose to $2,900,186 from $1,778,416, principally reflecting higher administration costs, including stock-based compensation for services.
- Nine-month R&D expense declined to $122,893 from $203,625. Management attributed this to completion of earlier process-development work.
- Interest expense increased to $1,506,111 from $1,309,336, including debt-discount amortization and accretion of debt premiums.
- Foreign-currency transaction loss was $2,053,010 for nine months, compared with $488,813 in the prior period. The filing attributes approximately $1.959 million of the current-period loss to unrepaid intercompany loans. Separately, other comprehensive income included a $2,215,762 currency-translation gain.
- Convertible-debt conversions drove substantial dilution: 17,343,368 common shares were issued for conversions during the nine months.
Outlook, risks and unusual items
- Going concern: Management stated that the losses, cash use, working-capital deficit and stockholders’ deficit raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months from issuance. The company said it did not have enough available cash to meet obligations over the next 12 months and needs additional financing.
- Development plans: Subject to sufficient financing, management planned to submit a clinical trial application in Q1 2021 and begin a first-in-human Phase Ib study in Q2 2021. These are plans, not assured milestones; PRP remained preclinical.
- Financing and dilution: The company issued $1,591,250 of convertible notes during the nine months, net of $126,000 in issue costs. Many notes have variable-price conversion terms, default provisions and potential penalties. Notes outstanding were convertible into approximately 104 million shares based on the quarter-end closing price, subject to contractual limits. After quarter-end, the company reported issuing 26,648,787 shares for note conversions in April and closing a $450,000 securities transaction with substantial warrant coverage.
- Other unusual items: A $984,810 stock-based compensation charge related to warrants issued for consulting services contributed to expenses. The quarter also included a $2,135,421 foreign-currency transaction loss and a $454,442 gain from changes in derivative fair value.
- COVID-19: Management said the pandemic’s effects on operations, financing access and future results were uncertain.
- Legal and control matters: The company is defending claims by former counsel seeking $151,031.50 plus interest and costs, and a separate claim by Regal Consulting seeking approximately $400,000 and 60,000 shares. Management reported disclosure controls were ineffective and identified continuing material weaknesses, including inadequate written procedures, segregation of duties, audit committee oversight and financial-reporting review.
- Related parties: The company leases office space from an entity owned by its CEO and his wife and reports director-related loans and amounts due. The filing also describes substantial executive compensation and deferred bonus amounts.
Important facts for investors to verify
- Available cash, near-term obligations, and the company’s ability to obtain enough financing to continue operations.
- Current principal, accrued interest, maturity status, default terms and conversion prices of each outstanding convertible note.
- Actual and potential share dilution, including April conversions, warrant terms, share reserves and the post-quarter $450,000 financing.
- Whether the planned CTA and first-in-human study milestones remain achievable, and the financing and regulatory requirements to reach them.
- Developments in the two disclosed legal disputes and whether recorded accruals adequately reflect potential exposure.
- Progress in remediating the disclosed material weaknesses in internal controls.